FDA Inspection 1084752 — Eversight
The FDA completed an inspection of Eversight on March 25, 2019 in Cleveland, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 25, 2019
- Fiscal Year
- 2019
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Cleveland, OH (United States)